Andy Oh is a senior partner working closely with Flagship’s Origination Partners and NewCo CEOs to help create an integrated view of long-term value potential and storytelling, including analytical value models for each of our enterprise companies. He also works on funding models and options for Flagship overall.
Andy was previously the Chief Financial Officer of Flagship-originated Rubius Therapeutics. While there, he raised more than $450M in capital, including its $277M initial public offering—the highest valued preclinical biotech IPO in Wall Street history at the time. Andy was also instrumental in negotiating and acquiring the company’s manufacturing facility to provide the clinical supply for Rubius’ red cell therapeutics. He brings more than 20 years of experience in finance and the biopharmaceutical industry to his role and has a strong track record of innovative corporate portfolio management, fundraising, capital allocation, and investor and performance management.
Andy has also served as a pharmaceutical analyst and portfolio manager at leading financial institutions, including Leerink (now SVB Leerink) and Fidelity. At Leerink, he was the Co-founder, Chief Investment Officer, and Chief Operating Officer of its Pharmaceutical Investments group and managed its Pharmaceutical fund which, over his three-year tenure, more than doubled its assets under management and significantly outperformed its benchmark. While at Fidelity, he managed the Fidelity Select Pharmaceuticals Portfolio fund which was rated by Lipper in 2013 as the number-one global health/biotechnology fund based on his three- and five-year performance. He also served as Fidelity’s senior analyst covering global pharmaceutical companies. Andy previously held similar roles at JP Morgan and Stifel Financial.
Andy received his M.B.A. from Northwestern University's Kellogg School of Management and his B.A. in Biology from Washington University in St. Louis.